This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis significantly improved outcomes after 24 weeks.
Medscape Medical News